Testmate Health has microengineered the power of a PCR machine into a low-cost, single-use disposable, test that can detect any DNA or RNA sequence with immediate results from the point-of-care to at-home. Our technological platform has proven lab equivalent accuracy even in challenging samples like urine.

Our first product addresses the $14B sexual health & women's health market, with the first disposable urine test that can detect chlamydia & gonorrhoea in all genders. Built for automated high scaled manufacturing, low COGs & high usability, Testmate addresses the rising silent epidemic of sexually transmitted infections, in a product format & price point that is finally compatible with the public health programs that are urgently tackling this problem.

News

24.05.2024 31st Prix Strategis crowns HeroSupport (startupticker.ch)
03.05.2024 USD 6 million to fight a silent epidemic (startupticker.ch)
06.12.2023 Prix Strategis 2024 Semi-finalists unveiled (startupticker.ch)
19.04.2022 Seven Earthshots accelerated from Geneva (startupticker.ch)
13.01.2022 Ten startups to explore Africa (startupticker.ch)
17.06.2021 W. A. de Vigier prize for six startups (startupticker.ch)

Milestones/News

01.06.2023 Completion of lab validation studies
30.04.2023 Completion of 1st stage human factors testing
21.09.2021 Closing of seed round
01.06.2021 Testmate Health kicks off at Biôpole

Documents

Videos and Presentations


De Vigier Winner 2021